Clinical Trials in Philadelphia

Showing 5301-5320 of 15,860 trials

Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Patients With AMD

NCT02463344

The purpose of his study is to evaluate the long term safety and tolerability of MA09-hRPE cellular therapy in patients with advanced dry Age-Related Macular Degeneration (AMD) from one to five years following the surgical procedure to implant the MA09-hRPE cells.

Age-Related Macular Degeneration

Astellas Institute for Regenerative Medicine11 participantsStarted Feb 2013

Los Angeles, California, United States • Miami, Florida, United States • Boston, Massachusetts, United States +1 more locations

COMPLETED< 1 mile

Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy Patients

NCT02445612

The purpose of this study is to evaluate the long term safety and tolerability of MA09-hRPE cellular therapy in patients with advanced Stargardt's Macular Dystrophy (SMD) from one to five years following the surgical procedure to implant the MA09-hRPE cells.

Stargardt's Macular Dystrophy

Astellas Institute for Regenerative Medicine13 participantsStarted Jul 2012

Los Angeles, California, United States • Miami, Florida, United States • Philadelphia, Pennsylvania, United States

TERMINATED< 1 mile

GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)

NCT03894020

An observational study to evaluate the natural progression of dry AMD in genetically defined subjects

Gyroscope Therapeutics Limited83 participantsStarted Jan 2019

Phoenix, Arizona, United States • Tucson, Arizona, United States • Beverly Hills, California, United States +68 more locations

Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Patients With AMD

Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy Patients

GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)

Find Trials by Condition in Philadelphia

Utility of Donor-Derived Cell Free DNA in Association With Gene Expression Profiling

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy

A Study of TAK-994 in Adults With Type 1 and Type 2 Narcolepsy

A Comparison of Extended Versus Conventional Duration of Enoxaparin Prophylaxis (i.e., Preventive Treatment) for Venous Thromboembolism (VTE, i.e., Blood Clots in the Veins) and Bleeding Event Risk in a Population With Acute Medical Illness

Comparison of the Risk of Venous Thromboembolism (i.e., Blood Clots in the Veins) and Bleeding Events in a Population of Obese Patients Receiving Higher-Dose or Extended-Duration Versus Conventional-Dose or Conventional-Duration of Prophylaxis (i.e., Preventive Treatment) With Enoxaparin

A Multicenter Prospective Observational Study to Derive and Verify the Performance of a Host-response Based Diagnostic Tool for Early Detection of Severe Infections.

Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease

A Study of LY3022855 In Participants With Breast or Prostate Cancer

Durvalumab and Tremelimumab for Pediatric Malignancies

Clareon Toric vs Eyhance Toric

A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma

Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS

A Study to Assess the Analgesic Efficacy and Safety of ASP0819 in Patients With Fibromyalgia

A Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male and Female Subjects With Limitations in Mobility

Effect of Celecoxib on Postoperative Analgesia and Disease Severity in AERD Patients with CRS

A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer